Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CDSCO

Exclusive-India considers policy change after cough syrup deaths - Modi's office

India is considering a change to its pharmaceutical industry policy after cough syrups made in the country were linked to the deaths of children overseas, according to a document from Prime Minister Narendra Modi's office, which noted that "important things" about the industry had been "overlooked".

Cough syrup deaths: Why is India’s drug regulator going after Dinesh Thakur and T Prashant Reddy?

Cough syrup deaths: Why is India’s drug regulator going after Dinesh Thakur and T Prashant Reddy?

It’s been over a week since public health activists Dinesh Thakur and T Prashant Reddy received an ominous notice from India’s Central Drugs Standard Control Organisation, warning them to stop “maligning the image of the institution and the nation at large”.

Pharma exporters body suspends membership of Maiden Pharmaceuticals

Pharma exporters body suspends membership of Maiden Pharmaceuticals

Pharmexcil had sought details after WHO named the firm in a medical product alert

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Gambia deaths | Pharma exporters body asks Maiden to share details

The incident has left a serious dent in the reputation of Indian pharma industry and exports, says Director-General

Drug regulator initiates probe after WHO links children deaths in Gambia to cough syrup made in India

Maiden Pharmaceutical Limited is the manufacturer licensed by the State drug controller for the products under reference, and holds manufacturing permission for these products

CDSCO falling short in effectively regulating the medical devices industry: Parliamentary panel

The Committee observed that the country has only 18 certified Medical Device Testing Laboratories that have been approved by CDSCO and that is grossly insufficient keeping in view the size of the country.

Zenara Pharma gets CDSCO nod to make copy of Pfizer’s Paxlovid

Combi pack of Nirmatrelvir, Ritonavir tablets is for patients with moderate symptoms of Covid-19

inkl

Read news from The Economist, FT, and more,
with one subscription

A new legislation that mirrors the old

A new legislation that mirrors the old

The New Drugs, Medical Devices and Cosmetics Bill is antiquated and needs to be revised

First case of infection from diabetes medication in India

First case of infection from diabetes medication in India

State drug controllers told to include warning for patients using SGLT2 inhibitors

Panel recommends regular market approval for Covishield and Covaxin

Panel recommends regular market approval for Covishield and Covaxin

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting regular market approval to COVID-19 vaccines, Covishield and Covaxin, in the adul

The Bedaquiline Question

The Bedaquiline Question

One of the increasingly contentious public health issues in India is the manner in which clinical trials are conducted for new drugs and the manner in which these new drugs are subsequently approved for use on Indian patients.

1 2

People

Ram Gopal Yadav

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Union Health Ministry

Maiden Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

399,788 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play